Clinical Trials

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Locally Advanced Rectal Cancer

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

108 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07331155 2026-03-09

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT05502250 2026-03-06

HOVON164HL

75 enrolled

Lymphoid

Hodgkin Disease

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07432984 2026-02-25

FMT-LUNG

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

33 enrolled

Colorectal Neoplasms

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoid

Lymphoma, Follicular

NCT07413354 2026-02-17

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Carcinoma, Hepatocellular

NCT05116085 2026-02-13

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

33 enrolled 11 charts

Colorectal Neoplasms

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT07390383 2026-02-09

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

110 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

37 enrolled

Nasopharyngeal Carcinoma

NCT07370337 2026-01-27

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

50 enrolled

Squamous Cell Carcinoma of External Auditory Canal

NCT07330037 2026-01-09

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

41 enrolled

NSCLC

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

25 enrolled

Nasopharyngeal Carcinoma

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05532319 2025-12-30

FRONT-1

64 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

30 enrolled

Gastric Cancer Peritoneal Metastases

NCT06722183 2025-12-24

FUTURE

33 enrolled

Colorectal Neoplasms

NCT07296705 2025-12-22

HARBOR

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT03736889 2025-12-17

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

200 enrolled

Other solid neoplasm

MSI-H/dMMR Solid Tumors

NCT05977673 2025-12-08

FIL_Tisle-HL

28 enrolled

Lymphoid

Hodgkin Disease, Lymphoma

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT07264647 2025-12-04

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

35 enrolled

Genitourinary

Renal Pelvic Carcinoma

NCT05622071 2025-11-17

HESTIA

50 enrolled

Carcinoma, Hepatocellular

NCT06010303 2025-11-17

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

118 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06139419 2025-11-17

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

114 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05909904 2025-10-07

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

160 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06529523 2025-10-07

Tislelizumab in People With Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT07196540 2025-09-29

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

78 enrolled

Digestive System Neoplasms

NCT06124378 2025-09-24

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

60 enrolled

Colonic Neoplasms

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

56 enrolled

Small Cell Lung Carcinoma

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

272 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

29 enrolled

Head and Neck Neoplasms

NCT05880082 2025-08-24

PPIO-004-EC001

118 enrolled

Esophageal Squamous Cell Carcinoma

NCT07128693 2025-08-19

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

38 enrolled

Mid-low Rectal Cancer

NCT05517330 2025-07-31

neoCHANCE-1

23 enrolled

Head and Neck Neoplasms

NCT07086456 2025-07-25

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05604560 2025-07-23

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

25 enrolled